

Table S1: CI analysis of sunitinib (SU) or vandetanib (Van) combined with eeyarestatin in TT cells. Analysis was conducted using the CampuSyn software (CacuSyn, Inc.). Descriptions are based on CI values and the recommendations of CalcusynSyn: <0.1, very strong synergism; 0.1–0.3, strong synergism; 0.3–0.7, synergism; 0.7–0.85, moderate synergism; 0.85–0.9, slight synergism; >1 antagonism. Abbreviation: Fa, fraction affected as tested by MTT assay after 48 hours with each indicated treatment.

EE	SU	Effect	CI	Description
0.1	0.01	0.06	0.71	Moderate Synergism
0.1	0.1	0.25	0.13	Strong Synergism
0.1	1.0	0.28	0.79	Moderate Synergism
1.0	0.01	0.13	0.49	Synergism
1.0	0.1	0.3	0.23	Strong Synergism
1.0	1.0	0.36	0.45	Synergism
2.0	0.01	0.21	0.53	Synergism
2.0	0.1	0.38	0.28	Strong Synergism
2.0	1.0	0.4	0.45	Synergism
4.0	0.01	0.42	0.44	Synergism
4.0	0.1	0.5	0.35	Synergism
4.0	1.0	0.7	0.18	Strong Synergism
6.0	0.01	0.63	0.33	Synergism
6.0	0.1	0.77	0.19	Strong Synergism
6.0	1.0	0.85	0.12	Strong Synergism

EE	Van	Effect	CI	Description
0.1	0.01	0.17	0.06	Very Strong Synergism
0.1	0.1	0.27	0.16	Strong Synergism
0.1	1.0	0.47	0.43	Synergism
1.0	0.01	0.28	0.2	Strong Synergism
1.0	0.1	0.42	0.16	Strong Synergism
1.0	1.0	0.59	0.27	Strong Synergism
2.0	0.01	0.5	0.17	Strong Synergism
2.0	0.1	0.63	0.12	Strong Synergism
2.0	1.0	0.68	0.21	Strong Synergism
4.0	0.01	0.88	0.06	Very Strong Synergism
4.0	0.1	0.92	0.04	Very Strong Synergism
4.0	1.0	0.93	0.049	Very Strong Synergism